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Abstract 
Identification of new biomarkers specific for various pathological conditions is an important field 
in medical sciences. Body fluids have emerging potential in biomarker studies especially those 
which are continuously available and can be collected by non- invasive means. Changes in the 
protein composition of body fluids such as tears, saliva, sweat, etc. may provide information on 
both local and systemic conditions of medical relevance. In this review, our aim is to discuss the 
quantitative proteomics techniques used in biomarker studies, and to present advances in 
quantitative body fluid proteomics of non-invasively collectable body fluids with relevance to 
biomarker identification. The advantages and limitations of the widely used quantitative 
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proteomics techniques are also presented. Based on the reviewed literature, we suggest an ideal 
pipeline for body fluid analyses aiming at biomarkers discoveries: starting from identification of 
biomarker candidates by shotgun quantitative proteomics or protein arrays, through verification 
of potential biomarkers by targeted mass spectrometry, to the antibody-based validation of 
biomarkers. The importance of body fluids as a rich source of biomarkers is discussed. 
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Introduction 
With the advances of diagnostic techniques there is an increasing demand for non- or minimally 
invasive methods in medical diagnosis. The constantly produced and continuously available body 
fluids which can be collected by non-invasive means such as tears, saliva, sweat etc. can provide 
a feasible alternative to cerebrospinal fluid, amniotic fluid, synovial fluid, bronchoalveolar lavage 
fluid, serum etc. for diagnostic purposes. In some cases the analysis of body fluids collected by 
invasive means cannot be avoided but considering the need for well-trained medical workers, the 
possibility of infections and complications, and costs of medical interventions required for the 
collection of the body fluids increase the need for utilization of non-invasively collectable body 
fluids. In this review we will present the diagnostic utility of those body fluids which can be 
collected without medical intervention, such as tears, saliva, sweat, nasal secretion, 
cervicovaginal secretion and urine and we will discuss the biomarkers discovered with the 
administration of proteomics techniques. 
Quantitative proteomics is a challenging part of proteomics, providing information not only on 
the presence or absence of proteins or protein isoforms, but also on their quantities. Typically, 
mass spectrometry, electrophoresis or immunological assays are utilized to give the relative or 
absolute quantities of proteins of interest. Absolute quantification determines the exact 
concentration of proteins, while in relative quantifications, only the relative change in protein 
quantity is compared in different conditions [1]. In most cases, relative quantification is sufficient 
to answer biological questions regarding changes in the amount of proteins following treatment, 
or when comparing two or more states. Relative quantification can give us an idea about protein-
level changes in different states and conditions, and can show us differentially expressed proteins. 
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The semi-quantitative ELISA, one- or two-dimensional gel electrophoresis [2] and most of mass 
spectrometry-based techniques are suitable for relative quantification (Table 1). 
For absolute quantification, a more elaborate experimental setup is needed. The simplest method 
for absolute quantification is the quantitative ELISA and the multiplex immunobead assay [3], 
however, these are rather expensive methods. Regarding mass spectrometry-based techniques, 
SRM-based targeted proteomics using various dilutions of purified, stable isotope labeled 
peptides is the method of choice [4]. Absolute quantification is required when the exact protein 
amount has biological significance, as in the case of stoichiometry analysis of protein complexes, 
biopharmaceutical applications for quality control or drug safety, inter- or intra-laboratory cross-
validations, biomarker studies, or when the amount of various proteins within the same sample is 
required [1].  
It is very hard to find the ideal quantitative proteomics technique applicable for the body fluid 
analysis; researchers willing to administrate such techniques should find the optimal solution 
matching their needs, considering the biological question, sample availability, costs, workload, 
and availability of mass spectrometers (Table 1). The presence of highly abundant proteins, such 
as α-amylase in saliva, dermcidin is sweat, lactotransferrin, lysozyme-C, etc. in tears and the low 
amount of available sample, especially when posttranslational modifications are to be studied, 
may require the administration of protein depletion and/or enrichment [5,6]. However the 
possible loss of quantitative information may hinder the wide application of these methods in the 
examination of non-invasively collectable body fluids. The administration of antibodies and the 
use of well-defined standards to monitor for example phosphoprotein enrichment [7] make 
possible the utilization of quantitative data. Another variation of protein enrichment is the 
utilization of antibodies against the digested peptides in the samples [8]. The Stable Isotope 
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Standards with Capture by Anti-Peptide Antibodies (SISCAPA) approach can be utilized to 
enrich specific peptides from different samples by using anti-peptide antibodies to capture 
endogenous peptides and spiked stable isotope-labeled internal standard peptides [9]. 
 
Biomarkers 
The two major fields utilizing quantitative proteomics in medicine are biomarker studies and 
identification of therapeutic targets; however, these two fields sometimes overlap. In some 
conditions, proteins are considered biomarkers when identified as having a central role in the 
normal or pathological function of the cells/tissues, and their presence or absence causes a 
malfunction leading to disease [10]. Consequently, biomarkers are at the same time targets for 
drug design and therapy [11]. In other cases, although the biomarkers can give information 
regarding alterations related to disease, they are not suitable targets for therapeutic intervention; 
their presence, absence or differential expression may be the consequence and not the cause of 
the pathological condition, hence, they cannot be used as target for therapies, nor can they 
explain the pathophysiological phenomena [12]. In this review, our aim is to show advances in 
the biomarker field aided by quantitative proteomics. According to the National Institutes of 
Health Biomarkers Definitions Working Group, a biomarker is “a characteristic that is 
objectively measured and evaluated as an indicator of normal biological processes, pathogenic 
processes, or pharmacologic responses to a therapeutic intervention” [13]. In recent years, studies 
aiming to identify biomarkers specific for different pathological conditions emerged, and 
hundreds of proteins were shown to be potential biomarkers specific for various diseases [14]. 
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In this review the potential biomarker term will be used for proteins whose level is significantly 
different between the disease and control groups, while the validated biomarker will refer to those 
proteins which were validated using an independent antibody-based technique. 
Despite the fact that advances in research techniques and intensive efforts in biomarker studies 
had led to identification of high numbers of potential biomarkers in the discovery phase, the 
number of FDA approved biomarkers is much less [15–21]. One reason for drastically decreasing 
the number of validated biomarkers as they go through the verification and validation processes 
can be the lack of standardized workflows [14]. Comparative studies examining protein profiles 
usually include less than ten samples per group, with different analytical methods detecting many 
differentially expressed proteins between the diseased and control groups. The number and 
identity of the differentially expressed proteins can vary from study to study, depending on the 
sensitivity of the applied analytical method, the size of the groups, and the patients enrolled in the 
study. Ideally, the only difference between the diseased and control groups should be the 
presence or absence of the disease [22]. In small groups, this is possible, however, when larger 
patient cohorts are enrolled, the presence of secondary disorders serves as hindrance to the 
analysis.  
The Clinical Proteomic Technologies for Cancer (CPTC) initiative established by the National 
Cancer Institute recommends a workflow for cancer biomarker development [14]. They suggest 
the use of SRM-based targeted proteomics method for verification of hundreds of potential 
biomarkers identified in the discovery phase. For verification, a large sample number is required. 
Ideally, hundreds of samples are analyzed, and after verification, the biomarkers can be subjected 
to the next step, the validation step. For validation, only few proteins should be chosen and tested 
on thousands of samples. Statistical analysis, including ROC curves [23] for biomarkers proved 
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to be convenient in the verification process can help identify the proteins with the highest 
specificity and sensitivity in discriminating between the control and diseased groups. 
Immunoassays are also very suitable for biomarker validation, allowing for analysis of large 
sample numbers in a short period of time. When multiple proteins have to be validated, the 
utilization of multiplex immunobead assays are more cost effective [3]. 
One of the bottlenecks of biomarker studies is sample availability. From pathophysiological point 
of view, it is of critical importance to analyze the tissue or the biological material in which the 
alteration happens, as well as the proximity of the material to the site of pathological alteration. 
In many cases however, these types of samples are not available for biomarker studies. For 
example, in case of pathological conditions affecting the retina; such as diabetic retinopathy, 
proliferative vitreoretinopathy, etc., the study of proteome changes of the retina would be 
important to understand the pathological mechanisms underlying the disease. On the other hand, 
for diagnostic purposes, the retina; which can be obtained only with highly invasive surgical 
intervention, is not an acceptable source for minimally- or non-invasive biomarker studies.  
In spite of the availability of advanced imaging methods, there is a high demand for laboratory 
diagnostic assays using biological samples or body fluids acquired by non-invasive or minimally 
invasive methods. Advances in proteomics and metabolomics techniques had led to improved 
sensitivity, and provided the possibility to detect protein or metabolite changes in body fluids 
which are not necessarily in proximity to the diseased area. For example, studies of tear or serum 
composition could identify potential biomarkers specific for retinal diseases [24,25].  
The emerging “omics” technologies provide new possibilities for identification of biomarkers 
form the continuously available body fluids that can be collected by non-invasive means, shifting 
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the focus from the study of tissue material obtained by autopsy and biopsy to the study of easily 
collectable and continuously available body fluids such as tears, saliva, sweat, etc. 
Tear fluid as a source of biomarkers for ocular and systemic diseases 
Tear fluid is a complex mixture of proteins, lipids, salts and other organic molecules produced by 
the lacrimal glands. Normally, the tear production rate is approximately 2 µl/min [26] and its 
typical protein concentration is 5-7 µg/µl [27]. Functions of the tear film are lubrication of the 
eye, delivery of nutrients and maintenance of the refractivity of the cornea [28]. Beside these 
roles, tear provides an effective chemical barrier on the surface of the eye via the secreted 
antimicrobial and immunomodulatory proteins (AMP), which provide protection against 
infections [29]. Currently, more than 1500 tear proteins have been identified by proteomics 
techniques [30–32]. Major tear proteins; such as lactotransferrin, lysozyme-C, prolactin-inducible 
protein, lacritin etc., are involved in the defense against pathogens [31], and their relatively high 
abundance makes these proteins the major antimicrobial proteins of tear. While many of the tear 
proteins are produced by the lacrimal glands, some of them originate from epithelial cells; such 
as dermcidin, defensins, etc., and there are also proteins filtered from the blood such as albumin 
[33,34]. 
The human tear has become one of the most investigated body fluids, being a possible source of 
biomarkers [30,31]. Tear fluid is one of the non-invasively obtainable body fluids that is 
relatively easy to collect, and its study may help understand the pathogenesis of ocular and some 
systemic diseases, in addition to aiding in the prediction of the outcome and scheduling follow-
ups for therapeutic sessions. Based on localization, tear can primarily reflect pathological 
conditions related to the anterior segment of the eye, but it can also provide information on the 
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retinal or vitreal status, and more broadly, information related to systemic changes can also be 
acquired by analysis of tear proteins (reviewed by [35,36]). The protein composition of tear was 
examined in various pathological conditions, and proteome-level changes were observed in case 
of contact lens wearers as well [37]. Analysis of tear protein profile can provide useful biological 
information on understanding the molecular mechanisms of ocular diseases; such as dry eye 
syndrome [38–41], blepharitis [42], climatic droplet keratopathy [43], diabetic retinopathy [25], 
keratoconus [44,45], mycotic keratitis [46] and vernal keratoconjunctivitis [47]. Changes in the 
tear proteome can also reflect systemic diseases such as multiple sclerosis [48] and Alzheimer’s 
disease [49]. SELDI-TOF data are available on tears of patients with Sjögren’s syndrome [50] 
and breast cancer [51,52], but the exact protein composition of the peaks characteristic for the 
pathological conditions is missing. Biomarkers for these pathological conditions identified by 
quantitative proteomics are listed in Table 2.  
Various immunological tests exist to study the concentration of pro- or anti-inflammatory 
markers in tears, in order to assess the inflammatory status in ocular or systemic diseases [53–
55]. Inflammatory changes were shown to be associated with glaucoma and neurodegenerative 
disorders such as Parkinson’s disease and multiple sclerosis [48,56–59]. The 47 potential and the 
10 validated biomarkers for various ocular or systematic diseases identified by quantitative 
proteomics experiments predict the clinical application of some of the identified biomarkers in 
the near future.  
Saliva – the easily accessible, continuously available source for biomarkers  
Saliva is a complex mixture secreted from major and minor salivary glands and from the gingival 
crevice [60]. It is composed of more than 99% water, making it a very dilute body fluid. The 
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remaining part of saliva is composed of various electrolytes, proteins, mucins and nitrogenous 
products such as urea [61]. Saliva contains more than 2000 proteins [62], the most abundant of 
which are α-amylase [63], mucins [64], proline rich peptides [65], cystatins [64] and serum 
albumin [66]. Although high variability in protein content was observed depending on collection 
time, sex, age, pathological conditions, the typical protein concentration of saliva is 0.7-2.4 
mg/ml [67–69]. Similarly to tear fluid, the abundant salivary proteins are part of the innate 
immune system, due to their antimicrobial activity, and their protective role from microbial 
proteases. The non-invasive collection and the continuous availability of the saliva make it an 
excellent source of biomarker studies; unsurprisingly, the protein composition of saliva has been 
analyzed by several workgroups, indicating its relevance to medical applications. A classical 2D 
gel electrophoresis-based study of saliva obtained from children with autism spectrum disorder 
revealed 8 down-regulated and 8 up-regulated salivary proteins as potential biomarkers for the 
disorder [70]. The advantage of multiplex measurements by chemical labeling with iTRAQ and 
label free quantification mass spectrometry of salivary proteins have been used for analysis of 
patients with breast cancer [71,72], malignant oral lesions [73], oral squamous cell carcinoma 
[74,75], chronic graft-versus-host disease [76,77], Sjögren's syndrome [78] and bisphosphonate-
related osteonecrosis of the jaw [79]. Differentially expressed proteins have been identified in 
these studies (Table 3), providing potential biomarkers to aid diagnosis and possibly enable for a 
deeper understanding of the molecular mechanisms involved in the pathogenesis of the studied 
diseases. SRM-based quantitative proteomics method for the analysis of O-glycosylated forms of 
salivary protein MUC7 in saliva of patients with rheumatoid arthritis has been developed and 
used to demonstrate the altered O-glycosylation pattern in rheumatoid arthritis, with a proposed 
role in diagnosis and treatment follow-up [80]. SELDI-TOF mass spectrometry method was used 
to identify biomarkers for fibromyalgia [81], oral squamous cell carcinoma [82,83] and Sjögren's 
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syndrome [84] (Table 3), and peaks showing significant differences are available for breast 
cancer [85] and oral mucositis [86]. From the so far identified 347 potential biomarkers for 
various diseases only 10 were validated by antibody-based techniques and are indeed suitable for 
population screening. This is highly relevant, especially in case of oral cancers, given the high 
prevalence of orals squamous cell carcinoma and its increasing tendency in the younger 
population [87,88]. 
Sweat biomarkers for local and systemic conditions 
The skin acts as an effective barrier against pathogens in the first line of host defense. Besides 
providing a physical barrier, the skin also creates a chemical barrier via antimicrobial and 
immunomodulatory proteins secreted by keratinocytes, sebocytes and epithelial cells [89]. Like 
saliva, sweat is a continuously secreted and highly diluted body fluid, its protein content provides 
an effective defense against pathogens, and is involved in tissue regeneration after injury [90]. 
The most abundant human sweat protein is dermcidin, though clusterin, prolactin-inducible 
protein, apolipoprotein D and serum albumin are highly expressed in sweat as well [91]. These 
proteins are essential to the formation of the chemical barrier of the skin, due to their 
antimicrobial activity [90,92], chaperone function [93] and antioxidant effect [94,95]. Sweat 
samples from patients with skin or systemic diseases such as ectodermal dysplasia, cystic 
fibrosis, atopic dermatitis and schizophrenia were analyzed using quantitative proteomics [96–
99]. It was demonstrated that in case of skin disorders, the level of proteins involved in the host 
defense and tissue regeneration were reduced in the samples of patients with ectodermal 
dysplasia and atopic dermatitis [96,99]. The typical concentration of sweat proteins is 0.1-0.4 
mg/ml [97,100] but it can vary depending on the exterior and interior conditions such as 
temperature, stress etc. [101,102]. It was proposed that reduction in the amount of proteins 
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involved in the immune homeostasis may contribute to the development of ectodermal dysplasia; 
therefore, they are classified as potential biomarkers and possible therapeutic targets in this 
disease. In case of systemic conditions, analysis of the sweat proteome has revealed proteins 
which were differentially expressed in schizophrenia (Table 4) [97]. In spite of the 180 potential 
and two validated (dermcidin and RNase7) biomarkers identified, many open questions remain in 
connection to the properties of sweat. Only limited information is available regarding (1) the 
normal rate of the sweat production, (2) the basal protein composition of the sweat collected at 
various body surfaces, (3) possible diurnal variations of the protein content, (4) the protein 
composition depending on the collection method etc., highlighting the role of proteomics in 
utilizing this continuously available, but very dilute and sometimes not so easy-to-collect body 
fluid for diagnostic purposes. 
Nasal secretion as a valuable source of potential biomarkers 
The nasal secretion has a protective role in the airways; its production rate and the protein content 
can vary substantially. Protein amounts produced between 0.8 and 32.7 mg/ml were observed 
depending on the collection methods [103,104]. Nasal discharge contains a lot of antimicrobial 
proteins; such as lysozyme-C, lactotransferrin, several types of defensins [105], also in addition 
to components of the adaptive immune system, such as immunoglobulins [106]. Compared to the 
other body fluids, a few number of publications report nasal mucus as a source of biomarkers; by 
quantitative proteomics only six potential biomarkers have been identified and only one of them 
has been validated so far (Table 5) [107]. As a result of various studies, more than 451 proteins 
were identified in the nasal mucus, and many of them are related to the immune system [107–
109]. Because of the anatomical localization, nasal mucus is the easily collectable body fluid with 
the closest proximity to the nervous system. This property is exemplified by the nasal 
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administration of drugs, enabling their direct delivery through the olphactory neurons or 
trigeminal nerve endings to the central nervous system [110,111]. Considering the fact that parts 
of the olphactory neurons are embedded into the nasal mucosa, their secretions should be 
detectable in the mucus. Based on the high sensitivity and versatility provided by the state-of-the-
art quantitative proteomics methods, the easy-to-collect nasal discharge is predicted to be a very 
valuable source for further biomarker studies. 
Cervicovaginal fluid as source for biomarkers for obstetrics and gynecology 
Vaginal fluid is a non-invasively collectable body fluid which may secrete from vagina, cervix or 
upper genital tract [112]. Vaginal discharge has an important function in the innate immunity and 
homeostasis and pathological conditions can significantly influence the balance in normal vaginal 
milieu leading to qualitative and quantitative protein alterations in vaginal secretion [113–115]. 
Many factors can influence the protein composition of the vaginal fluid, for example the varying 
levels and ratios of estrogens and progesterone resulting in variable amounts of protein yield, 
therefore it is practically impossible to quantify the normal amount of total protein compound in 
healthy cervicovaginal fluid [116]. Currently, more than 680 proteins have been identified in 
vaginal fluid and the majority of the identified proteins have a role in host defense [117]. The 
proteomic analysis of vaginal fluid can provide more information about the pathophysiological 
conditions affecting the female genital tract [118,119]. 63 potential biomarkers for pregnancy-
related problems such as intra-amniotic inflammation [112,120] and preterm labour/preeclampsia 
[121–125], cervical cancer [126] and HIV infection [127] were identified (Table 6) using 
quantitative proteomics techniques and six biomarkers were validated.  
Urine biomarkers for systemic and urogenital diseases  
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Urine is formed in the kidneys as a result of ultrafiltration of the plasma to eliminate waste 
products; such as urea and metabolites. Serum proteins are filtered based on their size and charge 
at the glomeruli, and are thereafter reabsorbed in the proximal renal tubules [128,129], thus, 
protein concentration in urine under physiological conditions is very low, usually between 0 and 
0.2 mg/ml [130] and the normal protein excretion is less than 150 mg/day [131]. This is about 
1000 times less compared to other body fluids such as plasma [132]. Excretion of more than 150 
mg/day protein is defined as proteinuria, and is indicative of glomerular or metabolic dysfunction 
[129]. 
Urine can be collected in large quantity and non-invasively. Therefore, despite the low protein 
concentration, adequate amounts of proteins can be collected from a single sample [131,133]. 
Another advantage of using urine as a body fluid for diagnosis is the possibility of collection of 
samples repeatedly, even over long periods of time. Under normal conditions, urine contains 
proteins originating from the blood and kidneys [134–139], making urine a good source for 
analysis of diseases affecting the kidney or the urogenital tract; such as kidney failure resulting 
from high blood pressure and diabetic nephropathy [140,141], prostate cancer [142,143], 
polycystic kidney disease [144], kidney chronic allograft dysfunction [145], chronic allograft 
nephropathy [146], congenital obstructive nephropathy [147], lupus nephritis [148], urolithiasis 
[149], in addition to urinary, renal and bladder cancer [150–161]. Besides urogenital and kidney 
dysfunctions, urinary proteomics has a great potential in biomarker studies of coronary artery 
atherosclerosis [162,163], obstructive sleep apnea [164], ovarian cancer [165], breast cancer 
[166] and sepsis [167,168]. 
Urine has become one of the most attractive body fluids in clinical proteomics [155], 
nevertheless, variability in protein concentration poses a hindrance to the analysis of samples. 
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This can be compensated for by standardization based on urinary creatinine [169] or urinary 
housekeeping peptides, which are present almost ubiquitously in human urine independently of 
age, sex, health, or drug administration [170]. Details on urine sample preparation have already 
been discussed in some recently published reviews [171–175]. However, urine samples require 
handling through a set of methods; such as centrifugal filtration, ultrafiltration, lyophilization or 
precipitation. Removal of albumin is sometimes required to improve identification of low-
abundance proteins [176].  
Urine proteome analysis may potentially unravel markers for cancers of urogenital or systemic 
origin including bladder [150–154,156,157,160,161], prostate [170], renal [158,159], breast [166] 
and ovarian cancers [165] (Table 7). There has been an increasing interest in developing urine 
biomarkers for the detection of renal allograft rejection as an alternative to percutaneous needle 
biopsy, which is costly and associated with significant patient morbidity and mortality [79]. The 
245 identified potential and 10 validated biomarkers for kidney-related and systemic diseases 
make urine a rich source of easy-to–collect, and continuously available source of biomarkers. 
Body fluids as part of the innate immune system 
The localization of the above mentioned body fluids correlates with the possible entry sites for 
microorganisms, implying the presence of a well-defined defense system. Besides mediating their 
physiological functions; body fluids also partake in the protection of the organism by providing a 
chemical barrier [29]. This chemical barrier is made up of the secretions of various glands and 
epithelial cells, and the characteristic composition of antimicrobial and immunomodulatory 
peptides (AMP) makes the AMP cocktail specific for different body fluids [177]. The 
composition of the AMP cocktail may determine which microbes can colonize our body, 
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providing unfavorable conditions for pathogen growth under physiological conditions. It was 
demonstrated that skin microbiome changes in response to various stimuli such as food, drugs, 
age, gender, physiological status etc., implying changes of the AMP cocktail [178]. These 
changes can be examined by the sensitive quantitative proteomics techniques, which are well 
suited to monitor AMP levels at various sites of the body in different physiological or 
pathological conditions [179].  
Proteomic analyses have revealed that highly abundant proteins observed in some body fluids; 
such as tears and sweat, are part of the first line defense. Biomarkers identified from body fluids 
by different research groups have enriched the library of proteins possessing antimicrobial or 
immunomodulatory properties (proteins with italics in the Table 2-7). More than half of the 
identified tear biomarkers for eight pathological conditions have antimicrobial or 
immunomodulatory functions. A similar phenomenon can be observed in case of vaginal fluid 
and nasal mucus as well, though only one proteomic study is available for the nasal mucus. In 
case of saliva and sweat, the number of the proteins having a role in host defense is high, making 
up in; most of the cases, more than half of the identified biomarkers, in some instances, where 
more than 130 proteins were identified approx. only 30% of the proteins belonged to the AMP 
family (Table 8). From an analytical point of view, this can also mean that utilizing mass 
spectrometers with high resolution mass analyzers or extensive sample fractionation, enrichment 
or depletion and identifying more than 100 proteins can reveal the proteome masked by the 
highly abundant proteins. The urine is unique in a sense that its distinct anatomical and 
physiological properties imply the presence of a different chemical barrier as compared to that of 
other body fluids [180]. The number of AMPs among the identified urine biomarkers is high but 
fall far less than those of other body fluids (Table 8). 
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Analysis of the chemical barrier components can provide valuable information; our group has 
identified lipocalin 1, lactotransferrin, lacritin, lysozyme-C, lipophilin A and immunoglobulin 
lambda chain as potential biomarkers for the proliferative stage of diabetic retinopathy [25], 
lipocalin 1, lacritin, lysozyme-C and dermcidin for Alzheimer’s disease [49]. Lactotransferrin, 
lipocalins, lysozyme-C, lacritin and dermcidin are involved in the immunologic and 
inflammatory processes and defense against pathogens [30,31,35,36]. It has been shown that 
lactotransferrin found in all body fluids is an active agent against microbes and parasites, and has 
been implicated in protection against cancer [90]. Lysozyme-C is a hydrolytic enzyme with 
muraminidase activity required for degradation of the bacterial cell wall [90], has antifungal 
activity [181] and protects against HIV infection [182]. Lipocalins are a family of lipid binding 
proteins, they play a role in host defense because of their protease inhibitor activity [183] and by 
sequestrating iron, they limit bacterial growth [184]. Lacritin is a secreted protein found in tears 
and saliva, it promotes secretion [185], epithelial cell proliferation [186], corneal wound healing 
[187], additionally, its C-terminal fragment has bactericidal activity [188]. Changes of tear AMP 
levels are likely not the cause but rather the consequence of diabetic retinopathy progression, 
hence, it can be used to develop bedside test for screening purposes. Currently, photographic 
methods and retinal image analysis to track neovascularization and increased vascular 
permeability in the retina can be used for screening [189–191], this, however, requires proper 
instruments, software, and well-trained human graders, making diagnosis available only in big 
screening centers. In order to make the screening widely accessible, easy-to-implement tests; 
which can be used by general practitioners, are needed. Potential biomarkers for different stages 
of diabetic retinopathy were identified, and their validation is in progress, making tear biomarkers 
novel tools for population screening, based on the pre-screening of a large number of patients and 
involving human graders only in positive or ambiguous cases [192]. 
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The composition of the AMP cocktail changes constantly, implying both qualitative and 
quantitative changes of the cocktail components, in order to adapt to various conditions. Most 
probably, composition of the chemical barrier is characteristic to the stimulus to which the 
organism has to adapt. Thus, changes of the composition of the host defense proteins in body 
fluids as a response to pathological conditions provide a feasible source for biomarker studies, 
which can be implemented using cutting edge quantitative proteomics analyses. 
Extracellular vesicles – future perspectives 
Different types of membrane vesicles of endosomal and plasma membrane origin are released in 
an evolutionally conserved manner into the extracellular environment by cells. These circulating 
microvesicles found in many types of body fluid and in extracellular space play an important role 
in cell signaling and intercellular communication [193–195]. According to their biogenesis, the 
extracellular vesicles can be grouped as apoptotic blebs, exosomes and microparticles, but the 
nomenclature is not clear for the latter two [196]. 
Exosomes, the membrane vesicles of endocytic origin are fragments from 40 to 100 nm secreted 
by most cell types. There are studies regarding exosome analysis of plasma [197], urine [198], 
amniotic fluid [199], saliva [200], bronchoalveolar lavage fluid [201], breast milk [202] etc.  
Microparticles are of cellular membrane origin shed from stressed or damaged cells. Their 
diameters ranges from 0.1 to 1.0 μm [203]. Almost 3700 proteins were identified in total plasma 
microparticles using proteomic methods [204,205]. 
Proteomics has traditionally focused on the study of extracellular vesicle (EVs) proteins found in 
body fluids, but the proteomic profiles are highly dependent on how EVs were isolated [206]. 
Alterations in EV protein levels observed in pathological conditions make exosomes a good 
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source for biomarker investigations [207]. More than 35000 proteins were found in the 
extracellular vesicles (http://www.microvesicles.org/) and using quantitative proteomics 
techniques 32 potential biomarkers for bladder and prostate cancer, kidney diseases, deep vein 
thrombosis and brain tumors were identified in body fluids. 10 of the potential biomarkers were 
validated using antibody-based methods (Table 9) [208–215]. 
 
Conclusion 
Based on the reviewed literature, hundreds of biomarker candidates have been identified, mainly 
from shotgun quantitative proteomic studies. Experiments using 2D electrophoresis, SELDI-
TOF, label-free quantification, iTRAQ and T T labeling on various body fluids have already 
provided more than 800 soluble potential biomarkers specific for different diseases. The number 
of verified potential biomarkers using targeted; preferentially SRM-based, approach in examined 
body fluids is 40, and the number of biomarkers validated by antibody-based methods is 34, 
highlighting the need for verification and validation studies. In our opinion, the NCI-CPTC 
Biomarker Development Pipeline suggested for cancer biomarker identification [14] should be 
used in all biomarker studies involving body fluids, regardless of the nature of the examined 
pathological condition. In some diseases, there are hundreds of potential biomarkers identified; in 
such cases the verification step using targeted proteomics followed by validation step using 
antibodies should be carried out (Figure 1). In those diseases where there are no data available, 
shotgun proteomics studies followed by targeted methods have to be applied in order to identify 
new biomarkers with high diagnostic value. In the field of body fluid proteomics, the need for 
non-invasively obtained, readily available biomarkers with diagnostic significance imposes 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
20 
 
pressure on state-of-the-art quantitative proteomics to utilize more body fluids, a rich source of 
yet undiscovered biomarkers. 
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Figure legends 
Figure 1. Body fluid analysis workflow for biomarker discoveries 
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Table 1 
Major 
considera
tion on 
method 
selection 
 2DE  
Metabo
lic 
labelin
g 
Chemi
cal 
labelin
g  
Label-
free 
quantifi
cation  
SRM  
HR-
SRM 
PRM  
SWAT
H  
Multipl
ex 
immun
obead 
assay 
SELDI
-TOF  
Relative 
quantific
ation 
possible possible 
possibl
e 
possible 
possibl
e 
possibl
e 
possibl
e 
possibl
e 
possible 
possibl
e 
Absolute 
quantific
ation 
not 
suitable 
not 
suitable 
not 
suitabl
e 
possible 
possibl
e 
possibl
e 
possibl
e 
not 
suitable 
possible 
not 
suitable 
Reprodu
cibility 
fair 
very 
good 
good 
very 
good 
very 
good 
very 
good 
very 
good 
good 
very 
good 
fair 
Sensitivit
y 
good, 
depends 
on the 
type of 
dye 
applied 
good, 
depends 
on the 
type of 
instrum
ent 
applied 
good, 
depend
s on 
the 
type of 
instrum
ent 
applied 
very 
good 
very 
good 
very 
good 
very 
good 
very 
good 
very 
good 
good 
Possibilit
y to 
analyze 
multiple 
samples 
in one 
run 
possible possible 
possibl
e 
not 
possible 
not 
possibl
e 
not 
possibl
e 
not 
possibl
e 
not 
possibl
e 
not 
posible 
not 
posible 
Possibilit
y to 
analyze 
multiple 
analytes 
in one 
run 
possible possible 
possibl
e 
possible 
possibl
e 
possibl
e 
possibl
e 
possibl
e 
possible 
possibl
e 
Type of 
mass 
spectrom
eter 
required 
 no 
specific 
require
ment 
 no 
specific 
require
ment 
 no 
specifi
c 
require
ment 
preferabl
y 
Orbitrap 
triple 
quadru
pole, 
QTRA
P 
 Q-
TOF  
quadru
pole-
Orbitra
p  
prefera
bly Q-
TOF  
not 
applicab
le 
SELDI-
TOF 
Manual 
work 
requirem
ent 
very 
high 
high high medium 
mediu
m 
mediu
m 
mediu
m 
mediu
m 
medium low 
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Special 
advanteg
es 
• Global 
changes 
of 
protein 
profiles 
can be 
examin
ed                                 
•Post-
ranslati
onal 
modific
ations 
can be 
detected                                            
• Any 
kind of 
sample 
can be 
analyze
d 
• 100% 
label 
incorpo
ration 
efficien
cy 
• Any 
kind of 
sample 
can be 
analyze
d 
• Any 
kind of 
sample 
can be 
analyzed 
• Wide 
dynam
ic 
range               
• 
Availa
bility 
of 
databa
ses 
contai
ning 
SRM 
transiti
ons 
• High 
resolut
ion                           
• All
transiti
ons 
can be 
monito
red 
• High 
resolut
ion          
• High 
mass 
accura
cy 
• High 
through
put                                      
• 
Allows 
the 
recordi
ng of 
the 
comple
te 
fragme
nt ion 
spectru
m                       
• 
Allows 
retrosp
ective 
protein 
analysi
s 
• Hihg 
specifici
ty
provide
d by the 
administ
ration of 
antibodi
es 
• 
Separat
ion on
the 
surface 
of the 
protein 
chip 
Limitatio
n 
• In 
case of 
body 
fluids 
with 
low 
sample 
volume 
sample 
pooling 
may be 
needed                                   
• 
Highly 
abunda
nt 
proteins 
can 
overloa
d the 
gel                                                
• 
Proteins 
with 
low 
abunda
nce may 
be 
undetec
• 
Typical
ly 
limited 
to cell 
culture 
experim
ents 
• 
Labelin
g 
efficien
cy is 
conditi
on 
depend
ent and 
require
s 
optimiz
ation               
• The 
presenc
e of 
byprod
ucts 
may 
cause 
proble
ms 
during 
data 
evaluat
ion 
• Many 
technical 
replicate
s are 
needed 
which  
increases 
instrume
nt time 
and 
costs 
• 
Availa
bility 
of 
peptid
e 
MS/M
S 
spectra 
is 
essenti
al to 
develo
p SRM 
metho
ds               
• SIL 
peptid
es may 
be 
require
d 
• 
Availa
bility 
of m/z 
of 
peptid
e 
precur
sors 
and 
their 
retenti
on 
times 
are 
essenti
al to 
develo
p HR-
SRM 
metho
ds 
• 
Availa
bility 
of m/z 
of 
peptide 
precurs
ors and 
their 
retenti
on 
times 
are 
essenti
al to 
develo
p PRM 
metho
ds 
• Low 
level of 
automa
tion                              
• Data 
analysi
s 
• 
Althoug
h there 
is 
possibili
ty to 
construc
t custom 
kits, the 
circumst
ances  
such as 
cost, 
time, 
optimiza
tion 
difficult
y due to 
the 
highly 
different 
concentr
ation of 
the 
individu
al 
analytes 
in the 
samples, 
• Lack 
of 
informa
tion on 
the 
identifi
ed 
proteins                                  
• Has 
not 
been 
support
ed by 
the 
manufa
cturer 
for 
many 
years 
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table favor 
the 
utilizati
on of 
already 
availabl
e kits, in 
this way 
analysis 
may be 
limited 
to what 
is 
provide
d by the 
vendors 
Utility in 
body 
fluid 
analysis 
suitable 
not 
suitable 
suitabl
e 
suitable, 
ideal for 
screens 
suitabl
e, ideal 
for 
validat
ions 
suitabl
e 
suitabl
e 
suitable
, ideal 
for 
screens 
suitable, 
ideal for 
validatio
ns 
 
suitable 
with 
serious 
limitati
ons 
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Table 2: Tear protein biomarkers identified by quantitative proteomics methods. 
The proteins in italic have antimicrobial and immunmodulatory effects, while the bold face refers 
to validated biomarkes. The other font settings (normal, underline, asterix) refer to the method by 
which the biomarkers were identified.  
Disease Method Potential biomarkers (Gene symbol) References 
Alzheimer’s 
disease 
SRM LACRT, LCN1, LYZ, DCD 49 
 
Blepharitis 2D SDS-
PAGE 
ALB, CST2, IGKCVIII, LACRT, LYZ, PIP, 
PKLR, SERPINA1 
42 
Climatic droplet 
keratopathy 
iTRAQ DKFZp686M08189, HP, JCHAIN, LACRT, 
PIGR 
43 
Diabetic 
retinopathy 
iTRAQ IGLC1, LACRT, LCN1, LTF, LYZ, SCGB1D1 25 
Dry eye syndrome iTRAQ 
2D SDS-
PAGE  
SELDI-
TOF* 
ALDH1A1, APOA1, AZGP1,C3, CST4, ENO1, 
EZR, GC, HP, IGHA1, IGHA2, IGHG3, IGLC1, 
JCHAIN, LACRT, LCN1*, LTF, LYZ*, ORM1, 
PIGR, PIP, PRDX1, PRP1, PRR4*, S100A11, 
S100A4 , S100A8*, S100A9, SCGB2A1, 
SERPINA1*, SMR3B*, TCN1, ZG16 
38,39,40,41 
Keratoconus Label-free 
quantification 
AZGP1, B2M, CLU, CTSB, CST1, CST4, FGA, 
IGHA1, IGHA2, IGKC, IGLC1, JCHAIN, 
KRT14, KRT5, LACRT, LCN1, LCN1P1, 
LGALS3BP, LTF, LYZ, PIGR, PIP, PROL1, 
PRR4, SLPI, ZG16B 
44,45 
Multiple sclerosis TMT SERPINA3  48 
Mycotic keratitis 2D SDS-
PAGE 
ALB, CST1, CST4, GLRX5, LCN1, PIP 46 
Vernal 
keratoconjunctivitis 
iTRAQ ALB, HPX, SCGB1D1, SCGB2A1, TF 47 
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Table 3: Salivary proteins identified as biomarkers revealed by quantitative proteomics. 
The proteins in italic have antimicrobial and immunmodulatory effects, while the bold face refers 
to validated biomarkes. The other font settings (normal, underline, asterix) refer to the method by 
which the biomarkers were identified.  
Disease Method Potential biomarkers (Gene symbol) References 
Autism spectrum 
disorder 
2D SDS-
PAGE 
ALB , AMY1A, ATP6V1C1, BPIFA2, CA6, CST5, 
FRAT1, GRTP1, IGHA1, JCHAIN, LCN1P1, MUC16, 
PIP, TF 
70 
Bisphosphonate-
related 
osteonecrosis of 
the jaw 
iTRAQ A1BG, A2ML1, ACTG2, ADH7, AKR1B10, 
ALDH3A1, ALDH9A1, ANXA1, ANXA2, ANXA4, 
APOA2, ARPC3, ARPC4, ATP5A1, ATP5B, BASP1, 
C1R, C5, CA2, CAB39L, CALML5, CAPN1, 
CARHSP1, CCT5, CCT8, CEACAM5, CHAD, 
CHI3L2, CLTC, CRABP2, CRNN, CSTA, CTSA, 
CUTA, DSP, ECM1, EEF1A1, EEF1G, EIF5A, EVPL, 
FAM49B, FKBP1A, FLG, GBP6, GNB2, GSTP1, 
H2AFY, HBD, HBG2, HIST1H1B, HIST1H2AA, 
HIST1H4A, HIST2H2BE, HIST2H2BF, HIST3H2A, 
HIST3H3, HSP90AA1, HSP90AB1, HSP90B1, 
HSPA1L, HSPB1, HSPD1, HTN1, IGHD, IGHG1, 
IGLC2, IL36A, IQGAP1, ITIH2, IVL, JUP, KRT10, 
KRT13, KRT14, KRT15, KRT16, KRT19, KRT25, 
KRT3, KRT4, KRT5, KRT6A, KRT73, KRT76, 
KRT78, LGALS7, LMNA, MGP, MMP9, MYH14, 
MYH9, MYL6, NPEPPS, ORM1, PCBP2, PDIA6, 
PFKL, PKP1, PLA2G2A, PLEC, PLS3, PPL, PRB3, 
PRDX1, PRDX6, RAB10, RDX, RHOA, RHOB, 
RNASE4, RNASET2, RNH1, RPLP0, RPS12, RPS25, 
RPS8, S100A14, S100A16, SAA4, SCEL, SCGB2A1, 
SERPINA1, SERPINA4, SERPINB2, SERPINB5, 
SERPIND1, SFN, TGM1, TGM3, TPM2, TPT1, 
TUBB1, UGP2, VCP, YWHAZ 
79 
Breast cancer iTRAQ AKR1E2, ALB, ALDOA, AMY1A, ANXA1, ANXA3, 
APOA1, ARHGDIB, AZGP1, B2M, BPIFA2, BPIFB2, 
C3, CA1, CA6, CALM1, CAT, CRISP3, CST1, CST2, 
CST3, CST4, CST5, CSTA, CSTB, DMBT1, ENO1, 
FABP5, FAM25A, FAM25B, FAM25C, FAM25G, 
71, 72 
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FGA, GSTP1, HBA1, HBB, HIST1H2BL, HIST1H4A, 
HIST2H2AB, HP, HPX, HTN1, IGHA1, IGHA2, 
IGHG1, IGHG2, IGHM, IGKC, IGLC1, JCHAIN, 
KLK1, KRT1, KRT13, KRT16, KRT4, KRT6C, KRT9, 
LCN1, LCN2, LPO, LTF, LYZ, MPO, MUC5B, NUCB2, 
PFN1, PIGR, PIP, PPIB, PRB2, PRDX1, PRH1, 
RPS27A, S100A4, S100A6, S100A7, S100A8, S100A9, 
S100A11, SPRR1A, SPRR3, TALDO1, TCN1, TF, 
TGM3, TKT, TMSB4X, TPM3, UBA52, UBB, UBC, 
VIM 
Chronic graft-
versus-host 
disease 
iTRAQ, 
Label-
free 
quantific
ation 
A2ML1, ACTB, ALDH3A1, ALDOA, AMY1A, 
ATP6AP1, AZGP1, B2M, BPIFA1, BPIFA2, BPIFB1, 
BPIFB2, C4orf40, C6orf58, C6A, CALM1, CALML5, 
CAMP, CEACAM5, CHI3L2, CRISP3, CRNN, CST1, 
CST2, CST3, CST4, CST5, CST6, CSTB, CTSB, CTSD, 
CYCS, DBI, DEFA1, DKFZp686C15213, 
DKFZp686K18196, DMBT1, DSC2, DSG1,  DSG3, 
ELANE, ENO1, ERO1A, EZR, FAM3B, FAM3D, 
FCGBP, FGA, FGB, FGG, GAPDH, GOLM1, GRN, 
GSTP1, HBA2, HBB, HP, HRP, HSPA5, HTN1, HTN3, 
IGHA1, IGHA2, IGHM, IGHV3-23, IGHV3-49, IGKC, 
IGKV4, IGL@, IL1RN, IGLC2, IGLL5, JCHAIN, 
KLK1, KRT1, KRT10, KRT16, KRT2, KRT6A, KRT9, 
KTR1, LCN1, LCN2, LEG1, LGALS3BP, LOC652694, 
LOC654188, LPO, LTA4H, LTF, LYPD3, LYZ, MPO, 
MUC5B, MUC7, NUCB2, P4HB, PGD, PGK1, PI3, 
PIGR, PIP, PKM, PKM2, PLTP, PPIB, PRB2, PRB3, 
PRB4, PRDX5, PRDX6, PRH1, PRR27, PRR4, 
PRTN3, PSAP, S100A7, S100A9, SCGB1A1, 
SERPINA3, SERPINB3, SERPINB5, SFN, SLPI, 
SMR3B, SPARCL1, SPINK7, SPRR2B, SPRR3, 
TALDO1, TCN1, TGM3, TIMP1, TKT, TTN, TXN, 
TXNDC17, Vκ3, YWHAZ, ZG16B 
76, 77 
Fibromyalgia SELDI-
TOF 
ARHGDIB, S100A8, S100A9 81 
Malignant lesions iTRAQ ACTB, MRLC2 73 
OSCC Label-
free 
A1BG, A2M, AHSG, APOA1, APOA2, APOA4, 
AZGP1, BPIFB2, C3, C4B, C4BPA, C6, C9, CD109, 
74, 75, 82, 
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quantific
ation 
SELDI-
TOF* 
CFB, CHIT1, CRISP3, CST1*, CST2, CST4, CSTB, 
DSG1, DSG3, EGF, EPHX1, FABP4, FAM49B, FGB, 
FGG, FSCN1, GSTM1, HBA1, HEXA, HIST1H2AA, 
HK3, HP, HPR, HPX, HSD17B4, ICAM3, IGHA1, 
IGHA2, JCHAIN, ILV102, ITIH2, ITIH4, IκVI, IκVIV, 
KLK1, KNG1, LCN2, LCP1, LPA, MIF, MUC5B, 
ORM1, PPIA, PRCP, PRTN3, RAC2, RETN, RPL7, 
SERPINA1, SERPINA6, SERPIND1, SLC4A1, 
SPINK5, TF, TLN1, TMEM132A, TPI1, TTR, 
TUBA1C, VIM, VTN, YWHAZ 
83 
Rheumatoid 
arthritis 
SRM MUC7 80 
Sjögren's 
syndrome 
2D SDS-
PAGE  
Label-
free 
quantific
ation 
SELDI-
TOF* 
ALB , AMY1A, AMY2B, ANXA1, APOA1, AZGP1, 
B2M*, BPIFA2, BPIFB2, C3, CA6*, CFB, CLU, CST1, 
CST2, CST3, CST5, DMBT1, HBA1, HBB, HTN1, 
HTN3, IGHA1, IGHA2, IGHG1, IGHG3, IGHM, IGKC, 
IGLC2, IGLL5, JCHAIN, KLK1, KRT1, KRT10, 
KRT13, KRT16, KRT4, KRT5, KRT6C, KRT9, LCN2, 
LGALS3BP, LPO, LTF*, LYZ, MGP, MUC5B, 
NUCB1, NUCB2, PIGR*, PIP, PLTP, PRB1, PRB2, 
RR27, PSAP, S100A8, S100A9, SERPINA1, SFN, 
SLPI, SMR3B, STATH, TF, ZG16B 
78, 84 
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Table 4: Sweat proteins identified as biomarkers by quantitative proteomics analyzes.  
The proteins in italic have antimicrobial and immunmodulatory effects, while the bold face refers 
to validated biomarkes. The other font settings (normal, underline, asterix) refer to the method by 
which the biomarkers were identified.  
Disease Method Potential biomarkers (Gene symbol) References 
Atopic 
dermatitis 
SELDI-TOF DCD 99 
Ectodermal 
dysplasia 
Label-free 
quantification 
A1BG, A2ML1, ACTN4, AHSG, ALAD, AMY1A, 
ANXA2, AP1B1, ARG1, ARHGDIB, ASAH1, 
ATP5B, ATRN, AZU1, BPIFA1, BPIFB1, BRN, 
CALM2, CAPG, CAT, CD44, CEACAM5, CHIT1, 
CLU, CNTRL, COPB2, COTL1, CPA4, CPE, CPM, 
CPNE3, CREG1, CRISP3, CTSA, CTSB, CTSD, 
CTSV, CYB5R2, CST1, CST2, CST4, CST5, CSTB, 
DCD, DDAH1, DDAH2, DDB1, DMD, DSC1, 
DSG1, DTD1, ECM1, EEF2, ELANE, ENDOD1, 
FABP5, FAHD1, FASN, FCGBP, FLNA, GBA, 
GGCT, GM2A, GPI, GSS, GSTP1, HARS2, HBA1, 
HEBP2, HRSP12, HSD17B4, HSPA5, IDS, IGHA2, 
IGHM, IGLL5, IL1RN, IL37, INTS7, JUP, KLK10, 
KLK11, KLK5, KLK7, KLK8, KRT33B, KRT35, 
KRT4, KRT73, KRT77, KRT82, KRT83, KRT85, 
LACRT, LAMP1, LCN1, LCN15, LDHA, LDHC, 
LEG1, LGALSL, LRG1, LYNX1, LYPD3, LYPD5, 
LYPLA1, LYZ, MDH1, MDH2, MMP8, MMP9, 
MUC5AC, MUC7, MYDGF, MYH9, NQO2, 
NUDT5, NUTF2, ORM2, PEBP1, PFN1, PGAM1, 
PGK1, PGM2, PIP, PITHD1, PLBD1, PM20D1, 
PNP, PPIB, PRCP, PSMA7, QPCT, RAB7A, 
REXO2, RNASE7, RNASET2, S100A18, S100A6, 
S100A8, S100A9, SBSN, SCGB1D2, SCGB2A2, 
SCPEP1, SERPINA12, SERPINB1, SERPINB13, 
SERPINB2, SERPINB8, SERPINC1, SIAE, SLPI, 
TALDO1, TF, TGM1, TOLLIP, VPS26A, ZG16B 
96 
Schizophrenia Label-free 
quantification, 
SRM* 
ANXA5*, ARG1*, AZGP1*, BLMH*, CALML3, 
CALML5*, CASP14*, CDSN*, CSTA*, DCD,  
DSG1*, FLNB, GAPDH*, GOT1, KLK11*, 
97 
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KRT10, KRT1B, KRT2, KRT6A, KRT9, MDH2, 
NUCB1, PARK7*, PEBP1*, PIP*, PKM, PRDX1*, 
S100A7*, TPI1, TXN* 
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Table 5: Biomarkers in nose water revealed by quantitative proteomics 
The proteins in italic have antimicrobial and immunmodulatory effects, while the bold face refers 
to validated biomarkes.  
 
Disease Method Potential biomarkers (Gene symbol) References 
Chronic 
rhinosinusitis 
Label-free 
quantification 
BP1A, BPIFB1, CHI3L1, LCP1, 
MUC5B, SERPINB10 
107 
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Table 6: Vaginal fluid protein biomarkers identified by quantitative proteomics methods. 
The proteins in italic have antimicrobial and immunmodulatory effects, while the bold face refers 
to validated biomarkes. The other font settings (normal, underline, asterix) refer to the method by 
which the biomarkers were identified.  
Disease Method Potential biomarkers (Gene symbol) References 
Cervical cancer Label-free 
quantification 
ACTN4, ACTR3, CFH, CRABP2, EEF1A1P5, 
GC, NAMPT, PGK1, SERPINB13, 
SERPINB3, YWHAE 
126 
HIV-infection iTRAQ PRTN3, SERPINA5 127 
Intra-amniotic 
inflammation 
 
Label-free 
quantification 
SELDI-TOF* 
 
A1BG, C3, CSTA, DEFA1*, DEFA2*, 
DEFA3*,  DSG3, DSP, FABP5, FN1, GC, HP, 
IGFBP1, IVL, KLK13, LMNA, LTF, LYZ, 
MMP9, ORM1, PPL, S100A7, S100A8*, 
S100A9*, SERPINA1, SERPINB3, 
SERPINB13, SPRR3, VCL 
112, 120 
Preterm labour/ 
preeclampsia 
2D-SDS-PAGE 
SELDI-TOF 
SRM* 
ACBP, ACTB, ALB AMBP, ANXA1, , 
ANXA3, APOA1, COL, CSTA, DSP*, 
FABP5, FGB, GC,  GGCT, GSTP1, HP, 
IL1RN, MICA, ORM1, PRDX1, PRDX2, 
RBP, S100A7, S100A9, SERPINA1, 
SERPINB1, SERPINB3, SFN*, SOD1, 
TCEA2, TF, THBS1*, TPM1, TXN 
 
 
121, 122, 
123, 124, 
125 
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Table 7: Protein biomarkers identified in urine by quantitative proteomics techniques. 
The proteins in italic have antimicrobial and immunmodulatory effects, while the bold face refers 
to validated biomarkes. The other font settings (normal, underline, asterix, etc.) refer to the 
method by which the biomarkers were identified.  
Disease Method Potential biomarkers (Gene symbol) References 
Bladder cancer 2D SDS-PAGE 
iTRAQ 
Label-free 
quantification
*
 
SRM
#
 
A2M, ALB, AFM
#
, AGT
#
, AHSG
#
, APOA1, 
APOA2
#
, APOA4, APOB, APOC2, APOC3, 
APOE, APOH APOL1
#
, AXL, AZGP1, BCAN, 
C2, C3, C9
#
, CADM1
*
, CALR, CD44
*
, CDH2, 
CEL, CLEC4G, CNTN1, COL15A1, CP, 
CPQ, CST3, CTSA, EGF, F2
#
, FABP5, FBN1, 
FGA, FGB, FGG,  FN1, GAA, GC, GGH, 
GUCA2A, GUSB , HPX
*
, HSPG2, IGFBP7, 
ITIH4
#
, G LS7, MGAM, MMP2, MMP9, 
NID1, ORM1, PGA5, PLG
#
, PRCP, PRG4, 
PROZ, PSAP
*
, QPCT
*
, QSOX1, RBP4, 
ROBO4, S100A7, S100P, SAA4, SDC4, 
SERPINA1
*#
, SERPINC1, SOD3, SPP1
*
, 
TF
*#
, THBS1
#
, TNXB, TTR, UMOD
*
, YIPF3 
150, 151, 
152, 153, 
154, 156, 
157, 160, 
161 
Breast cancer Label-free 
quantification 
ALB, AGRN, ANXA1, AHSG, APOA4, C3, 
C9orf131, CA1, CSTA, DNAH8, HBA1, 
IGHG2,  IκV, ITIH4, LCN2, LRRC36, LTF, 
MAST4, NEGR1, ORM1, PGA3, SPARCL1, 
SULF2, VTN 
166 
Chronic allograft 
nephropathy 
SELDI-TOF B2M 146 
Congenital 
obstructive 
nephropathy 
Label-free 
quantification 
SRM 
ARG1, AMY1A, AMY2B, CASP14, CDH1, 
CUBN, EGF, FLNB, IGFBP7, KLK1, 
LRRC15, PDCD1LG2, PTGDS, SERPINA5, 
TGM3, VCAN 
147 
Coronary artery 
atherosclerosis 
Label-free 
quantification 
COL1A1, COL1A3 163 
Diabetic 
nephropathy 
2D SDS-PAGE 
iTRAQ 
APOA4, CP, EGF, PIP, SERPINA1, TTR 140, 141 
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Kidney chronic 
allograft 
dysfunction 
Label-free 
quantification 
KNG1, UMOD 145 
Lupus nephritis 2D SDS-PAGE AMBP, AZGP1, IGKC 148 
Obstructive sleep 
apnea 
2D SDS-PAGE AMBP, EGLN2, KAT2B, KLK1, ORM2, 
TNC, TRIB2,  UCN3, UMOD, ZFP36, 
ZNF81 
164 
Ovarian cancer 2D SDS-PAGE RNASE2 165 
Polycystic kidney 
disease 
iTRAQ 
SRM 
A2M, ADGRF5, ADGRL1, ADM, AGT, 
AFM, ALB, AMY1A, AMY2A, ANGPTL2, 
ANPEP, ANXA11, APOA1, APOA2, APOA4, 
APOB, APOD, APOE, ART3, AXL, B2M, 
B3GNT2, B4GAT1, BHMT, BLMH, C1RL, 
C3, C4B, C5, C7, CA1, CADM1, CASP14, 
CD14, CD248, CDH11, CDH13, CDH2, 
CDH6, CDHR5, CEL, CETP, CFB, CFD, 
CFH, CHL1, CILP, CILP2, CNTN1, 
COL15A1, COL6A1, CPN2, CRB2, CRYAB, 
CRYM, CST6, DPEP1, DSC1, EGF, FAT4, 
FBN1, FBP1, FCGR3B, FGB, FGG, FLG, 
FLRT2, FN1, FREM2, GAA, GALNS, GAS6, 
GC, GGCT, GOLM1, GP5, GPC1, GPC3, 
GPC4, GSTM3, GSTT1, GUCA2B, HP, HPX, 
HRG, HSPB1, HSPG2, HYAL1, ICAM2, 
IGFBP6, IGFBP7, ISLR, ITFG1, ITIH1, 
ITIH2, KRT4, KRT6A, LCAT, LGALS3BP, 
LRRC15, MAN1A1, MB, MCAM, MFI2, 
MME, MMRN2, MUC20, MXRA8, MYOC, 
OGN, OLR1, ORM1, OSCAR, PCDH1, 
PCDHGC3, PDCD6 , PFN1, PHPT1, PON1, 
PROM2, PSAP, PSG11, PSG9, PVALB, 
PVR, PVRL1, PVRL3, QPCT, QSOX1, 
RBP4, REG1A, ROBO4, SDF4, SDK1, 
SERPINA1, SERPINA4, SERPINA5, 
SERPINC1, SERPIND1, SERPINF1, 
SERPINI1, SH3BGRL, SPRR3, SUSD2, TF, 
TGM4, TNXB, TPP1, TTR, VASN, 
144 
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XPNPEP2 
Prostate cancer 2D SDS-PAGE S100A9 143 
Renal cell 
carcinoma 
SELDI-TOF ALB, IGLC, MASP2, SECTM1, VMO1 158, 159 
Sepsis iTRAQ A1BG, AFM, AMY2A, CDH1, CEACAM8, 
DPP4, GM2A, HP, HSPG2, IκV, KRT1, 
KRT10, KRT16, KRT5, KRT9, LAMP1, 
LCN1, MUC1, SELENBP1 
167, 168 
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Table 8: Number of antimicrobial peptides/proteins among the identified potential 
biomarkers 
Disease Body 
fluid 
Technique Number of 
potential 
biomarkers 
Number 
of AMPs 
MS instrument type 
Blepharitis Tear 2D SDS-PAGE 8 5 Q-TOF  
Climatic droplet 
keratopathy 
Tear iTRAQ 5 4 Q-TOF  
Diabetic retinopathy Tear iTRAQ 6 5 4000QTRAP  
Dry eye syndrome Tear iTRAQ 
SELDI-TOF 
33 21 Q-TOF  
LTQ-Orbitrap  
PBS-IIc ProteinChip 
Reader  
Keratoconus Tear Label-free 
quantification 
26 19 LTQ-Orbitrap 
Multiple sclerosis Tear TMT 1 0 LTQ-Orbitrap 
Mycotic keratitis Tear 2D SDS-PAGE 6 4 MALDI-TOF  
Vernal 
keratoconjunctivitis 
Tear iTRAQ 5 0 MALDI TOF-TOF  
Autism spectrum 
disorder 
Saliva 2D SDS-PAGE 14 7 Q-TOF  
Bisphosphonate-related 
osteonecrosis of the jaw 
Saliva iTRAQ 135 41 LTQ-Orbitrap 
Breast cancer Saliva iTRAQ 92 50 Q-TOF 
Chronic graft-versus-
host disease 
Saliva iTRAQ 
Label-free 
quantification 
140 46 TOF-TOF 
LTQ-Orbitrap 
Fibromyalgia Saliva SELDI-TOF 3 2 ProteinChip SELDI 
system  
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Malignant lesions Saliva iTRAQ 2 0 LTQ-LIT  
Rheumatoid arthritis Saliva SRM 1 0 5500QTRAP  
OSCC Saliva Label-free 
quantification 
SELDI-TOF 
76 30 LTQ-Orbitrap  
ProteinChip biology 
system 
Sjögren's syndrome Saliva Label-free 
quantification 
65 35 LTQ-Orbitrap  
Atopic dermatitis Sweat SELDI-TOF 1 1 Protein Chip Array  
Ectodermal dysplasia Sweat Label-free 
quantification 
159 42 LTQ-Orbitrap 
Schizophrenia Sweat Label-free 
quantification 
SRM 
30 9 LTQ-Orbitrap  
TSQ Quantum Ultra 
 
Chronic rhinosinusitis Nose 
water 
Label-free 
quantification 
6 3 LTQ- Orbitrap  
Bladder cancer Urine 2D SDS-PAGE 
iTRAQ 
Label-free 
quantification 
SRM 
79 14 MALDI-TOF  
LTQ-Orbitrap 
4000QTRAP  
Chronic allograft 
nephropathy 
Urine SELDI-TOF 1 1 Protein Chip Array  
Breast cancer Urine Label-free 
quantification 
24 9 LTQ-Orbitrap 
Congenital obstructive 
nephropathy 
Urine Label-free 
quantification 
16 1 LTQ-Orbitrap 
Coronary artery 
atherosclerosis 
Urine Label-free 
quantification 
2 1 LTQ-Orbitrap  
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Diabetic nephropathy Urine 2D SDS-PAGE 6 1 SELDI-TOF  
5600Triple-TOF  
Kidney chronic 
allograft dysfunction 
Urine Label-free 
quantification 
2 1 LTQ-Orbitrap 
Lupus nephritis Urine 2D SDS-PAGE 3 2 TOF-TOF 
Obstructive sleep apnea Urine 2D SDS-PAGE 11 1 MALDI-TOF  
Polycystic kidney 
disease 
Urine iTRAQ 151 19 LTQ-Orbitrap 
Prostate cancer Urine 2D SDS-PAGE 1 1 MALDI-TOF  
Renal cell carcinoma Urine SELDI-TOF 5 3 ProteinChip Reader 
PCS 4,000  
Sepsis Urine iTRAQ 19 4 LTQ-Orbitrap  
Cervical cancer Vaginal 
fluid 
Label-free 
quantification 
11 3 LTQ-Orbitrap 
HIV-infection Vaginal 
fluid 
iTRAQ 2 1 MALDI-TOF-TOF 
Intra-amniotic 
inflammation 
Vaginal 
fluid 
Label-free 
quantification 
SELDI-TOF 
29 12 LTQ-Orbitrap 
Protein Chip Array  
Preterm labour/ 
preeclampsia 
Vaginal 
fluid 
2D-SDS-PAGE 
SELDI-TOF 
SRM 
34 13 LTQ-LIT 
MALDI-TOF 
Linear ion trap 
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Table 9: Extracellular vesicle biomarkers identified by quantitative proteomics methods.  
The proteins in italic have antimicrobial and immunmodulatory effects, while the bold face refers 
to validated biomarkes. The other font settings (normal, underline) refer to the method by which 
the biomarkers were identified.  
Disease Method Potential biomarkers (Gene symbol) References 
Bladder cancer Label-free 
quantification, 
Dimethyl labeling 
TACSTD2, GSA, RETN, GPRC5A 211, 212 
Brain tumor 2D-DIGE EEF1B, PSMA1, 3DPGH, ARRDC2, NANS, 
CENP-P, EIF3B, PCNA, MTAP, GPNMB, 
EGFR, HSC70, HSPD1 
215 
Deep venous 
thrombosis 
2D SDS-PAGE, 
iTRAQ,  
Gal3BP, A2M 213,214 
Nephropathy/ 
nephrotic 
syndrome 
Label-free 
quantification,  
 
ANPEP, VASN, SERPINA1, CP,  209, 210 
Prostate cancer Label-free 
quantification 
FASN, XPO1, PDCD6IP, CD9, ENO1 208 
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Figure 1 
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Graphical abstract 
 
